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Collagen-derived dipeptide prolyl hydroxyproline directly binds to 
Foxg1 to change its conformation and inhibit the interaction with 
Runx2 
Collagen-derived dipeptide prolyl hydroxyproline (Pro-Hyp) is involved in the 
proliferation and differentiation of various types of cultured cells. To elucidate 
the mechanism underlying Pro-Hyp actions during osteoblast differentiation, we 
hypothesized that proteins binding to Pro-Hyp serve to mediate cellular signaling, 
affecting Runx2 expression. Recently, we performed the characterization of 
Foxg1, that it enhances Runx2 expression in the presence of Pro-Hyp. Our 
findings indicate that Pro-Hyp directly binds to the Foxg1 recombinant protein, 
which leads to the structural alteration of the Foxg1 protein. In addition, Foxg1 
appears to interact with Runx2 in the absence of Pro-Hyp, with Pro-Hyp 
disrupting the interaction between Foxg1 and Runx2. Collectively, our results 
indicate that the Pro-Hyp bound Foxg1 alters the structured conformation of 
Foxg1, resulting in conformational changes that lead to dissociation from Runx2. 
These novel findings suggest that during osteoblast differentiation, Pro-Hyp 
mediates Runx2 activity though directly binding to Foxg1 and increases Runx2 
expression. 
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Introduction 
Collagen contains approximately 90% of the organic compound in the osseous tissue 
and is one of the important components of osseous tissue [1]. Osseous tissue is 
maintained by remodeling with osteoblasts and osteoclasts, while collagen is 
synthesized using osteoblasts as the main component of bone matrix protein [2, 3]. In 
osteoclasts, old collagen is degraded into collagen peptide (CPT) by enzymatic cleavage 
of the bone matrix [4, 5]. One of the major components of CPT is Pro-Hyp, which is 
characterized as mostly abundant dipeptides in collagen. Moreover, Pro-Hyp which 
known to possess physiological functions, appear in blood at high concentrations after 
oral ingestion of collagen hydrolysate [6, 7]. In addition, it has been reported that Hyp-
Gly and Glu-Hyp-Gly detected in the blood after oral ingestion of fish collagen 
hydrolysate [8]. Collagen peptide promotes proliferation and differentiation on various 
types of cultured cell, including osteoblasts [9], chondrocytes [10, 11], and fibroblasts 
[12]. We previously demonstrated that Pro-Hyp promotes the differentiation of 
osteoblasts by increasing Runx2 mRNA expression. In addition, Runx2/Cbfa1 is an 
important transcription factor necessary for osteoblast differentiation and bone 
formation [13]. Indeed, Runx2 binds to the promoter region of genes such as Col1a1, 
osteocalcin, and osterix [14].  
Forkhead box g1 (Foxg1; formerly known as BF-1, Brain Factor 1) is a transcriptional 
regulatory factor belonging to the forkhead protein family and has a forkhead type DNA 
binding region at the center [15]. In the molecular structure of Foxg1, proline- and 
histidine-rich regions and poly glutamine repeat sequences are present on the N-
terminal side and the serine-rich region on the C-terminal side [16]. Foxg1 is also 
important for the formation of the cerebral cortex and inner ear [17-19]. Previously, we 
have focused on osteoblast differentiation, and although Foxg1 inhibits osteoblast 
differentiation [20], we have found that Foxg1 is required for alkaline phosphatase 
(ALP) activity and the gene expressions of master genes, such as osteocalcin, Col1α1, 
and osterix, during osteoblast differentiation [21].  
Foxg1 is structurally and functionally highly conserved to Foxo1, which acts as a 
Runx2 hetero-dimer partner. Interestingly, it has recently been reported that the binding 
between Foxo1 and synthetic compounds having a N-heterocycle are important in 
regulating gluconeogenesis related gene expression in primary hepatocytes [22]. Foxo1 
directly interacts with Runx2 and up-regulates these target genes. Thus, we 
hypothesized that Foxg1 directly binds to Pro-Hyp and leads to conformational changes 
of the Foxg1 complex formation. Finally, we examined the interaction between Foxg1 
and Runx2 involving Pro-Hyp binding.  
In this study, we have performed recombinant binding assays with Pro-Hyp and Foxg1, 
and revealed the Pro-Hyp binding region on Foxg1. In addition, using GST pull-down 
assays, Pro-Hyp bound Foxg1 appears to dissociate Runx2 from the Foxg1 complex. 
Collectively, our novel findings indicate that Pro-Hyp promotes Runx2 mediated 
osteoblast differentiation through directly binding to Foxg1. 
  
Materials and Methods 
cDNA plasmids 
Foxg1 and Runx2 mouse cDNA were amplified using polymerase chain reaction (PCR) 
from single strand cDNA obtained from mouse brain and the mouse osteoblastic cell 
line MC3T3-E1. Full-length mFoxg1 cDNA were subcloned into the bacterial 
expression vector pGEX4T3 as the GST-Foxg1 fusion protein as previously described 
[20]. The GST-Foxg1 expression plasmids expressing the truncated forms of Foxg1 
(Foxg1A: amino acids 1–171, Foxg1B: amino acids 172–263, Foxg1C: amino acids 
264–375, Foxg1D: amino acids 376–481) were subcloned into pGEX4T3 through PCR 
using mFoxg1-pGEX4T3 as a template. The primer sequences are listed in Table 1. The 
Foxg1A region contains a poly-Q sequence, while the Foxg1B region contains a DNA 
binding domain. The Foxg1D region contains the lysine-specific demethylase 5B-
binding region. To generate the protein expression vector without the GST tag (pFex), 
we reconstructed pFex by polymerase chain reaction using the pGEX4T3 vector as a 
template. The Foxg1 and Runx2 cDNA fragments were inserted into the EcoR1 sites of 
the pFex vector, respectively. All sequences were verified using automatic DNA 
sequencing. 
  
Recombinant proteins 
 The prepared plasmids were transformed into the BL21 strain and the transformed 
bacteria were cultured at 37˚C until the OD 600 had reached 0.6. IPTG (0.4 mM) was 
added and the culturing continued for 3 h in LB-medium at 28˚C (shaking at 180 rpm). 
Bacterial lysates containing the proteins were prepared by sonication in PBSP buffer 
containing 137 mM NaCl, 10 mM Na2HPO4, 2.7 mM KCl, 1.8 mM KH2PO4, 10% 
Glycerol, 1 mM DTT, protease inhibitor tablets, and 1 mM PMSF, and centrifuged at 
7500 rpm for 5 m for collection of the GST fusion protein. The expression of 
recombinant proteins was confirmed using Western blot analysis. 
  
Western blot analysis 
Recombinant proteins were separated on 4–20% (wt/vol) gradient polyacrylamide gels 
by SDS-polyacrylamide gel electrophoresis (PAGE) and transferred to PVDF 
membranes by using trans blot turbo (BIO-RAD). Membranes were incubated for 1 h in 
TBS (50 mM Tris-HCl, 138 mM NaCl, 2.7 mM KCl) -Tween 20 containing 5%(wt/vol) 
nonfat dry milk, and then exposed to a 1:1,000 dilution of rabbit polyclonal antiserum 
anti-Foxg1 (Abcam, catalog no. ab18259) or anti-Runx2 (Cell signaling, catalog 
no.84865) at room temperature for 1 h. The membranes were washed and incubated 
with 1:2,000 anti-rabbit IgG (H+L) conjugated to HRP for 45 m at room temperature, 
and the blots were developed using the ECL plus Western blot analysis detection 
system. In addition, the Anti-GST antibody conjugated with HRP (GE Health care, 
catalog no. RPN1236) was used for the detection of the GST fusion protein (1:5000). 
  
Magnetic beads pull-down assay 
Pro-Hyp-Gly five times (Pro-Hyp-Gly)5 NH2- linked magnetic beads or Glu-Hyp-Gly 
five times (Glu-Hyp-Gly)5 NH2- linked magnetic beads or control magnetic beads (6µl) 
(TAMAGAWA seiki Co.,Ltd) were equilibrated with binding buffer (150 mM KCl, 10 
mM HEPES (pH = 7.8), 1 mM EDTA, 10% Glycerol, 1 mM DTT, Protease inhibitor 
tablets) and incubated with 2 mg of Foxg1 full-length protein or Foxg1 truncated 
mutants recombinant proteins at 4˚C for overnight with occasional agitation. After 
being washed three times with binding buffer, bound proteins were eluted with SDS-
PAGE sample buffer and were subjected to SDS-PAGE and Western blot analysis. To 
define specific binding to Pro-Hyp, excess amounts of free Pro-Hyp or Pro-Pro (10 mM, 
100 mM) or Hyp-Gly (5 mM, 50 mM) were used for the analysis. Hyp-Gly could not 
dissolve at a concentration of 1M, therefore the competition assay was performed 5 mM 
and 50 mM that half the amount of other peptides. 
  
Glutathione S-transferase (GST) pull-down assays 
The GST-Foxg1 recombinant protein was purified with Glutathione Sepharose 4B 
Beads (GE Health care). Purified GST-Foxg1 was incubated with tag-free Runx2 
recombinant protein on ice for 3 h. Foxg1-Runx2 complexes were precipitated with 
Glutathione Sepharose 4B Beads. The beads were then washed using PBSP buffer as 
previously described. The presence of Runx2 in the precipitates was detected using 
Western blot analysis with the rabbit anti-Runx2 antibody (Cell signaling, catalog 
no.84865) 
  
Protease digestion assays 
The plasmid Foxg1-pGEX4T3 or pFex-Runx2 was used to synthesize the GST-Foxg1 
or pFex-Runx2 recombinant protein in E. coli. The purified GST-Foxg1 or pFex-Runx2 
recombinant protein was subsequently aliquoted into 20 µL volumes; 30 µL of PBS 
with or without Pro-Hyp were then added. These mixtures were incubated for 10 m at 
room temperature, separated into 25 µL aliquots, and 5 µL of solubilized trypsin (wako 
202-15951) was added. Protease digestion was allowed to proceed for 1 m at 37˚C. The 
reaction was then terminated by the addition of 10 µL of sample buffer and boiling for 5 
m. SDS-PAGE and Western blot analyses were then performed using the rabbit anti-
Foxg1 antibody (abcam ab18259) or rabbit anti-Runx2 antibody (cell signaling 8486S). 
  
Results and Discussion 
To demonstrate whether Pro-Hyp directly binds to Foxg1, we prepared the recombinant 
Foxg1 protein and (Pro-Hyp-Gly) 5 linked magnetic beads or (Glu-Hyp-Gly)5 linked 
magnetic beads or control magnetic beads for the binding assay. The magnetic beads 
were linked to (Pro-Hyp-Gly)5 or (Glu-Hyp-Gly)5 of the N terminus. We considered 
that Pro-Hyp linked magnetic beads could not detect Foxg1 bound to Pro-Hyp, as 
molecular size of Pro-Hyp is very small. For this reason, to make it easy to detection 
sensitivity of Pro-Hyp bound Foxg1, we used (Pro-Hyp-Gly)5 linked magnetic beads as 
positive control beads. In addition, considering that repeated binding of Pro-Hyp causes 
steric hindrance, Gly which is low molecule weight and neutral amino acid was inserted 
between Pro-Hyp and Pro-Hyp. We used (Glu-Hyp-Gly)5 magnetic beads as negative 
control beads. Because Glu-Hyp-Gly which is similar to Pro-Hyp-Gly was reported as a 
biologically active substance [23]. To confirm binding specificity to Pro-Hyp, free Pro-
Hyp or Pro-Pro was added at a concentration of 10 mM or 100 mM to perform the 
competition assay. And free Hyp-Gly was added at a concentration of 5 mM or 50 mM 
to perform the competition assay. The binding between Foxg1 and (Pro-Hyp-Gly)5 
magnetic beads dissociation was dependent on Pro-Hyp concentration (Fig 1a, lanes 2, 
3 and 4). In addition, the binding between Foxg1 and (Pro-Hyp-Gly)5 magnetic beads 
dissociation was occurred at only high concentration of Pro-Pro (Fig 1a, lanes 6, 7 and 
8). Whereas, the binding between Foxg1 and (Pro-Hyp-Gly)5 magnetic beads 
dissociation wasn’t dependent on Hyp-Gly concentration (Fig 1a, lanes 10, 11and 12) 
On the other hand, no binding between Foxg1 and the (Glu-Hyp-Gly)5 magnetic beads 
was observed in the absence or presence of Pro-Hyp (Fig 1b, lane 2, 3 and 4). Foxg1 
didn’t bind to control magnetic beads (data not shown). These data indicate that Pro-
Hyp directly binds to Foxg1 and Pro-Pro partially binds to Foxg1. 
To characterize the Pro-Hyp binding domain in the Foxg1 protein, we next prepared the 
truncated mutants. Due to the recognition site of available Foxg1 antibodies for the 
GST-fused Foxg1, truncated proteins were adapted as shown in Figure 2a. Each 
truncated mutant of the Foxg1 recombinant protein was combined and incubated with 
(Pro-Hyp-Gly)5 magnetic beads or control magnetic beads. The anti-GST antibody was 
used for Western blot analysis to detect each Foxg1 truncated mutant. As a result, both 
GST-Foxg1A and GST-Foxg1B appear to bind to (Pro-Hyp-Gly)5 magnetic beads (Fig. 
2b lanes 3 and 6). However, no observation of the binding against GST-Foxg1C or 
GST-Foxg1D was detected (Fig. 2b lanes 8, 9, 11, 12, 14, and 15). These results clearly 
demonstrate that Pro-Hyp binds to both the Foxg1A and B region (amino acids 1–172, 
173–263)  
To clarify the Foxg1 conformation changes with or without Pro-Hyp, we examined the 
differential sensitivity of trypsin as a protease digestion assay. The GST-Foxg1 protein 
or GST-Foxg1 with Pro-Hyp was then subject to trypsin digestion into the GST-Foxg1 
protein with or without Pro-Hyp, and the digested products were detected using Western 
blot analysis. As shown in Figure 3, in the absence of Pro-Hyp, GST-Foxg1 indicated a 
high sensitivity to trypsin (Fig. 3, lane 2). In the presence of Pro-Hyp, however, trypsin 
resistant 50 kDa and 30 kDa Foxg1 fragments were observed (Fig. 3, lane 4). Indeed, 
these fragments indicated that the C-terminal region was in Foxg1, since it was used for 
the antibody to detect Foxg1 amino acid 400 to the C-terminals. Runx2 indicated a high 
sensitivity to trypsin in the absence or presence of Pro-Hyp (data not shown). It is 
suggested that Pro-Hyp hasn’t trypsin inhibitory activity. Therefore, these data suggest 
that Pro-Hyp binding alters the Foxg1 structural conformation or Pro-Hyp binds Foxg1 
at basic amino acid which trypsin cleavages. Taken together with the previous result 
shown in Figure 2b, we considered that Pro-Hyp binds to the DNA binding region of 
Foxg1, with the resulting conformational change of Foxg1 or steric effects of Pro-Hyp 
on Foxg1 having the possibility to change the DNA affinity of Foxg1. 
Based on previously reported results, Foxo1 directly interacts with Runx2 during 
osteoblast differentiation [24]. Finally, we examined the interaction between Foxg1 and 
Runx2 with Pro-Hyp binding. As shown by GST pull-down assay in Figure 4a, the 
recombinant Runx2 full-length protein and the GST-Foxg1 protein were prepared from 
E.coli. GST-Foxg1 strictly interacted with Runx2 in the absence of Pro-Hyp (Fig. 4b, 
lane 4). Surprisingly, the interaction of GST-Foxg1 with Runx2 was dissociated in the 
presence of Pro-Hyp (Fig. 4b, lane 5). These results suggest that Pro-Hyp prevents the 
interaction between Foxg1 and Runx2. In HaCaT cells, Foxg1 interacts with Foxo1, 
negatively regulating the transcriptional activity of p21Cip1 [25]. The Interaction of 
Runx2 with Foxo1 induces the expression of osteocalcin, which is the target gene of 
Runx2 [14]. We previously clarified that Pro-Hyp induces Runx2 to mediate osteoblast 
differentiation [26]. Altogether, we determined that Pro-Hyp mediated the prevention of 
the interaction between Foxg1 and Runx2 and may contribute to the strength of the 
interaction between Runx2 and Foxo1. These bindings may lead to osteoblast 
differentiation.  
 Focusing on the metabolites of CPT, few reports exist indicating that collagen-derived 
dipeptides are transported subcellularly by a peptide transporter [27, 28]. In addition, 
cyclic glycine-proline binds to IGF1 and leads to the regulation of the interaction 
between IGF1 and the IGF binding protein [29]. These results consider that Pro-Hyp is 
imported subcellularly through the peptide transporter and exists as the Pro-Hyp binding 
protein in the subcellular region.  
Runx2 binds to the 360–456 amino acid residue in the Foxo1 protein [14]. This region 
has high homology with Foxg1 on the C-terminal side. Collectively, these reports 
expect that the C-terminal region of Foxg1 is critical for the interaction with Runx2. 
This study clarified that Pro-Hyp binding to Foxg1 leads to the structural alteration of 
the C-terminal region in Foxg1. On the other hand, the N-terminal of Foxg1 could not 
be observed (data not shown). Taken together, the structural alteration of the C-terminal 
of Foxg1, induced by Pro-Hyp binding to the DNA binding region of Foxg1, may 
trigger the dissociation of the interaction between Foxg1 and Runx2. Although, it is 
unclear whether physiological cellular concentration of Pro-Hyp in osteoblastic cells. 
Although, Pro-Hyp previously reported to be detected in the blood after the oral 
ingestion of collagen hydrolysate (Cmax = 60.65 ± 5.74 µM) [6]. Moreover, oral 
ingested [14C] Pro-Hyp is distributed in bone, cartilage and skin [30]. We have 
previously reported that 0.1 − 1 mM of Pro-Hyp induces differentiation of MC3T3-E1 
which is osteoblastic cells [26]. Accordingly, Pro-Hyp was used at a concentration of 
0.1mM in this paper. However, we can not discuss these Pro-Hyp effects are able to 
occur in physiological or pharmacological conditions. In conclusion, we considered that 
Pro-Hyp prevents the interaction between Foxg1 and Runx2 and may be part of the 
osteoblast differentiation mechanism. 
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Figure 1. Foxg1 binding to (Pro-Hyp-Gly)5 magnetic beads in a Pro-Hyp specific 
manner. 
a, Competition assay. Foxg1 extracts were mixed with (Pro-Hyp-Gly)5 magnetic beads. 
At that time, an excess amount of Pro-Hyp or Pro-Pro was added at a concentration of 
10 mM (lanes 3 and 7), and 100 mM (lanes 4 and 8), Hyp-Gly was added at a 
concentration of 5 mM (lane 11), 50 mM (lane 12) and a competition inhibition assay 
was performed followed by Western blot analysis for Foxg1. Pro-Hyp, Pro-Pro or Hyp-
Gly was not added to lanes 2 or 6 or 10. The equivalent of 0.1 µg of Foxg1 protein 
extracts were used as input (lanes 1, 5 and 9). Detailed methods are described in this 
report. 
b, Competition assay. Foxg1 extracts were mixed with (Glu-Hyp-Gly)5 magnetic beads. 
At that time, an excess amount of Pro-Hyp was added at a concentration of 10 mM (lane 
3), 100 mM (lane 4), and a competition inhibition assay was performed followed by 
Western blot analysis for Foxg1. Pro-Hyp was not added to lane 2. The equivalent of 
0.1 µg of Foxg1 protein extracts were used as input (lane 1). Detailed methods are 
described in this report. 
  
Figure 2. A and B region of Foxg1 binding to (Pro-Hyp-Gly)5 magnetic beads. 
a, Schematic showing the region structure of Foxg1 and the truncated mutants. The amino 
acid numbers of each mutant are labeled. Foxg1 was deleted as follows (Foxg1-A: amino 
acid 1–171, Foxg1-B: amino acid 172–263, Foxg1-C: amino acid 264–374, and Foxg1-
D: amino acid 375–481) and GST tag was added, and E. coli produced a recombinant 
protein. We produced various GST-Foxg1 truncated mutants (GST-Foxg1-A 43 kDa 
(lane 2) GST-Foxg1-B 36 kDa (lane 3) GST-Foxg1-C 37 kDa (lane 4) GST-Foxg1-D 36 
kDa (lane 5) and GST 25 kDa (lane 1) followed by Western blot for GST (Fig.2a).  
b, Binding assay. The Foxg1 truncated mutants or only GST tag was mixed with control 
magnet beads (lanes 2, 5, 8, 11, 14) or (Pro-Hyp-Gly)5 magnetic beads (lanes 3, 6, 9, 
12, 15). They were then analyzed using Western blot analysis using the anti-GST 
antibody. Foxg1 and GST protein extracts were used as the input (lanes 1, 4, 7, 10, 13). 
Detailed methods are described in this report. 
  
Figure 3. Pro-Hyp induces a Foxg1 conformational change. 
Purified GST-Foxg1 fusion protein was incubated at 37˚C for two consecutive 10 m and 
1 m periods of time. For the first period, Pro-Hyp was added to 0.1 mM, respectively, to 
lanes 3 and 4. An equal volume of water was added to lanes 1 and 2. For the second 
period, trypsin was added to 0.1 µg. Foxg1 was digested with trypsin and analyzed by 
Western blot analysis (lanes 2 and 4). Detailed methods are described in this report. 
  
 
Figure 4. Pro-Hyp inhibits the interaction of Foxg1 with Runx2. 
a. Runx2 recombinant protein was produced by E. coli (lane 1). GST-Foxg1 recombinant 
protein was produced by E. coli (lane 2). 
b. Runx2 was incubated with glutathione sepharose beads containing bacterially 
expressed GST or GST-Foxg1, these proteins, and then analyzed using Western blot 
analysis using the Runx2 antibody. A mixture of Runx2 and GST (lanes 2 and 3) or 
GST-Foxg1 (lanes 4 and 5) proteins was precipitated by glutathione 4B beads. At that 
time, Pro-Hyp was added at a concentration of 0.1 mM (lanes 3 and 5). Lanes 2 and 4 
were not administered Pro-Hyp. The Runx2 protein extract was used as the input (lane 
1). Detailed methods are described in this report. 
